The Prescription We're Not Writing: Sleep Assessment in T2D Care
- t2diabetesnetwork
- 1 day ago
- 6 min read
Written by Clare Koning, RN, PhD | August 2026 | 6 min read
Key Highlights
✅ Sleep under 7 hours raises T2D risk by 18%; over 8 hours raises it by 13%
✅ OSA affects an estimated 23–86% of patients with T2D and obesity
✅ Intermittent hypoxia from OSA independently drives insulin resistance
✅ The STOP-Bang questionnaire provides validated OSA risk stratification
✅ CBT-I improves insomnia severity and depressive symptoms in people with T2D
If you ask most people with T2D whether their healthcare provider has ever asked about their sleep, the answer is almost certainly no. Sleep rarely appears on a diabetes visit template. It is not part of standard glycemic review. It does not get a checkbox alongside blood pressure, foot care, and retinal screening. And yet a March 2026 editorial in The Lancet Diabetes & Endocrinology calls sleep "one of the most feasible, scalable, and cost-effective strategies" for metabolic disease prevention, without the side effects of pharmacological or dietary interventions. This is not a fringe view. It is the current position of one of the world's leading metabolic disease journals.
The gap between the evidence and clinical practice is significant. This post is about closing it.
Sleep Duration, Quality, and T2D Risk: The Numbers
The relationship between sleep and T2D risk is not subtle. A comprehensive 2025 systematic review and meta-analysis published in Annals of Medicine, pooling data from across PubMed, Embase, Web of Science, and Scopus found a U-shaped relationship between nighttime sleep duration and T2D risk. Sleeping fewer than seven hours is associated with an odds ratio of 1.18 for T2D. Sleeping more than eight hours is associated with an odds ratio of 1.13. The sweet spot is seven to eight hours, and deviation in either direction carries measurable metabolic cost.
But duration is only one dimension. Poor sleep quality – fragmented sleep, difficulty falling or staying asleep, non-restorative sleep – worsens glycemic control independently of how long a person sleeps. The same meta-analysis confirmed that both poor sleep quality and insufficient sleep duration "work together to significantly elevate HbA1c levels."
A 2025 study in Medicine enrolled 294 patients with T2D and found that those with sleep disorders had significantly higher fasting plasma glucose, 2-hour plasma glucose, HbA1c, and HOMA-IR compared to those without, after controlling for other variables. Poor sleep in this population was not correlated noise. It was a signal.
The mechanisms are well-established. Sleep deprivation disrupts cortisol secretion, elevates ghrelin (driving appetite and caloric intake), suppresses leptin, impairs pancreatic beta-cell function, and increases sympathetic nervous system activity, all of which promote insulin resistance. These are not indirect pathways. They are the same mechanisms targeted by glucose-lowering medications.
The Chronotype Gap: When You Sleep Matters Too
One of the more clinically underappreciated findings from the sleep-T2D literature is that when people sleep matters, not just how long. Evening chronotype, being a "night owl," with a natural tendency toward later sleep and wake times, is independently associated with higher T2D risk, metabolic syndrome, and worse glycemic control. The mechanism is circadian misalignment: when sleep timing is shifted out of phase with biological rhythms, the metabolic consequences accumulate even when total sleep duration is adequate.
For patients who report sleeping late and waking late, this is relevant clinical information. It is also a reminder that the "do you get enough sleep?" question is too simple. Asking about sleep timing, consistency, and quality captures a more complete picture.
Obstructive Sleep Apnea: The Underdiagnosed Driver of Insulin Resistance
Obstructive sleep apnea is common in the general population, affecting an estimated 17.5% of Canadians over 45 according to the Canadian Longitudinal Study on Aging, which enrolled 27,210 participants. In people with T2D and obesity, the prevalence is dramatically higher.
A 2025 narrative review in the Journal of Clinical Medicine, the most current synthesis of the OSA–T2D relationship, cites polysomnographically confirmed OSA prevalence ranging from 18% in primary care T2D populations to 58% in older cohorts and up to 86% in obese patients with T2D. Most are undiagnosed.
The relationship is bidirectional. OSA causes T2D, and T2D worsens OSA. The shared mechanism at the centre of both is intermittent hypoxia. When the upper airway repeatedly collapses during sleep, oxygen saturation drops, the body triggers a stress response, cortisol and catecholamines surge, sympathetic nervous system activity increases, and glucose metabolism is disrupted through multiple converging pathways: suppressed adiponectin, elevated resistin, impaired beta-cell function, and direct HIF-1α-mediated insulin resistance.
What this means clinically is important: a patient whose HbA1c is not responding to medication adjustments, who is gaining weight despite efforts, who is fatigued despite "sleeping enough," may have undiagnosed moderate-to-severe OSA driving insulin resistance in parallel with whatever glycemic interventions are in place. In a study cited by the JCM 2025 review, apnea hypoxic index (AHI) severity in T2D patients was positively correlated with HbA1c after controlling for multiple confounders, and the effect size of AHI on HbA1c was comparable to that of some hypoglycemic agents.
OSA also worsens all major diabetes complications. The review confirms associations between untreated OSA in T2D and higher rates of nephropathy, with a 1.73-fold increased risk of diabetic kidney disease, as well as peripheral neuropathy, retinopathy, and cardiovascular disease. These are not peripheral concerns. They are the outcomes diabetes management is designed to prevent.
The STOP-Bang: A Canadian Tool, Underused in Canada
The STOP-Bang questionnaire, the most widely used OSA screening tool globally, was developed at the University of Toronto by Dr. Frances Chung and colleagues. It consists of eight yes/no questions covering: snoring, tiredness, observed apnea, high blood pressure, BMI, age, neck circumference, and sex (male).
The score ranges from 0 to 8.
Score 0–2: Low risk for moderate-to-severe OSA
Score 3–4: Intermediate risk - consider further assessment
Score ≥5: High risk - refer for home sleep apnea testing or polysomnography
It takes under two minutes to complete in clinic, can be self-administered in a waiting room, and has been validated across primary care, surgical, and chronic disease populations. A May 2026 review in ACOFP Voice confirmed that despite the tool's simplicity and clinical utility, OSA screening remains systematically absent from routine primary care, including diabetes visits.
In the T2D population specifically, STOP-Bang performance is striking. One cross-sectional study of 529 patients with T2D found that 59% scored ≥5, placing them in the high-risk category. High STOP-Bang scores in T2D patients were independently associated with 10-year fatal and non-fatal coronary heart disease risk. Screening is not just detecting sleep disorders, in this population, it is detecting cardiovascular risk.
What CBT-I Offers: Non-Pharmacological Sleep Treatment in T2D
For patients whose primary sleep complaint is insomnia, difficulty falling or staying asleep, or non-restorative sleep without a structural airway cause, Cognitive Behavioural Therapy for Insomnia (CBT-I) is the first-line recommended treatment in all major sleep guidelines, recommended over pharmacotherapy even in older adults.
A 2024 randomised controlled trial tested online CBT-I in adults with T2D and insomnia symptoms. The CBT-I group showed significantly greater reductions in insomnia severity and depressive symptoms compared to usual care. Per-protocol analysis showed a trend toward reduced HbA1c (−2.10 mmol/mol), though the trial was underpowered to reach statistical significance on glycemic outcomes. Lifestyle factors, including physical activity and dietary patterns, partially mediated the intervention's effect, suggesting that improving sleep may enable other health behaviours in this population.
Digital CBT-I programs are now available in Canada and may be accessible to patients on waitlists for in-person therapy or psychological services. For patients with T2D and comorbid insomnia, discussing CBT-I as part of diabetes care is a low-risk, evidence-informed intervention that addresses mood, sleep, and potentially glycemic control simultaneously.
A Five-Minute Addition to Every Diabetes Consultation
The evidence is clear enough to support a practical recommendation: add sleep assessment to the standard T2D visit.
This does not require a dedicated sleep appointment, specialist referral, or new clinical infrastructure. It requires three questions and a validated tool:
"How many hours of sleep do you typically get on a weeknight?" (Target: 7–8 hours)
"How would you rate your sleep quality? Do you feel rested in the morning?" (Screen for insomnia)
Administer the STOP-Bang questionnaire. (Score ≥5: refer for home sleep apnea test)
Patients with scores suggesting poor sleep quality, short or long duration, and high STOP-Bang scores should be followed up.
Sleep is scalable, cost-effective, and evidence-based. It is also the metabolic intervention most consistently absent from the diabetes appointment.
